| 1 |
Gandhi BV, Bahadur MM, Dodeja H, et al. Systemic fungal infections in renal diseases[J]. J Postgrad Med, 2005, 51(Suppl 1)：S30-S36.
|
| 2 |
Kontoyiannis DP, Marr KA, Park BJ，et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database[J]. Clin Infect Dis, 2010, 50(8)：1091-1100.
|
| 3 |
Uppuluri P, Alqarihi A, Ibrahim AS. Mucormycoses[M]//Encyclopedia of Mycology. Amsterdam: Elsevier, 2021：600-612.
|
| 4 |
Alqarihi A, Kontoyiannis DP, Ibrahim AS. Mucormycosis in 2023: an update on pathogenesis and management[J]. Front Cell Infect Microbiol, 2023, 13：1254919.
|
| 5 |
Palomba E, Colaneri M, Azzarà C, et al. Epidemiology, clinical manifestations, and outcome of mucormycosis in solid organ transplant recipients: a systematic review of reported cases[J]. Open Forum Infect Dis, 2024, 11(6)：ofae043.
|
| 6 |
Tinmouth J, Baker J, Gardiner G. Gastrointestinal mucormycosis in a renal transplant patient[J]. Can J Gastroenterol, 2001, 15(4)：269-271.
|
| 7 |
Ju JH, Park HS, Shin MJ, et al. Successful treatment of massive lower gastrointestinal bleeding caused by mixed infection of cytomegalovirus and mucormycosis in a renal transplant recipient[J]. Am J Nephrol, 2001, 21(3)：232-236.
|
| 8 |
Sehgal A, Raghavendran M, Kumar D, et al. Rhinocerebral mucormycosis causing basilar artery aneurysm with concomitant fungal colonic perforation in renal allograft recipient: a case report[J]. Transplantation, 2004, 78(6)：949-950.
|
| 9 |
Echo A, Hovsepian RV, Shen GK. Localized cecal zygomycosis following renal transplantation[J]. Transpl Infect Dis, 2005, 7(2)：68-70.
|
| 10 |
Prasad N, Ram R, Satti Reddy V, et al. Non-fatal gastric mucormycosis in a renal transplant patient and review of the literature[J]. Transpl Infect Dis, 2006, 8(4)：237-241.
|
| 11 |
Lalwani S, Govindasamy M, Gupta M, et al. Gastrointestinal mucormycosis-four cases with different risk factors, involving different anatomical sites[J]. Indian J Gastroenterol, 2012, 31(3)：139-143.
|
| 12 |
Johnson JB, Affolter KE, Samadder NJ. A rare cause of hematochezia: colon mucormycosis[J]. Clin Gastroenterol Hepatol, 2013, 11(8)：A22.
|
| 13 |
Barnajian M, Gioia W, Iordache F, et al. Mucormycosis-induced colon perforation after renal transplantation[J]. Surg Infect (Larchmt), 2014, 15(5)：665-666.
|
| 14 |
Nandwani A, Jha PK, Duggal R, et al. Invasive gastric mucormycosis and cytomegalovirus infection in an ABO incompatible renal transplant recipient[J]. Indian J Nephrol, 2015, 25(6)：373-376.
|
| 15 |
Busbait S, AlMusa Z, Al Duhileb M, et al. A cecal mucormycosis mass mimicking colon cancer in a patient with renal transplant: a case report and literature review[J]. Am J Case Rep, 2020, 21：e926325.
|
| 16 |
Chamilos G, Lewis RE, Kontoyiannis DP. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis[J]. Clin Infect Dis, 2008, 47(4)：503-509.
|
| 17 |
Sharma A, Alam MA, Dhoundiyal S, et al. Review on mucormycosis: pathogenesis, epidemiology, microbiology and diagnosis[J]. Infect Disord Drug Targets, 2024, 24(1)：e220823220209.
|
| 18 |
Lanternier F, Sun HY, Ribaud P, et al. Mucormycosis in organ and stem cell transplant recipients[J]. Clin Infect Dis, 2012, 54(11)：1629-1636.
|
| 19 |
Cornely OA, Alastruey-Izquierdo A, Arenz D, et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium[J]. Lancet Infect Dis, 2019, 19(12)：e405-e421.
|
| 20 |
Gebremariam T, Gu Y, Singh S, et al. Combination treatment of liposomal amphotericin B and isavuconazole is synergistic in treating experimental mucormycosis[J]. J Antimicrob Chemother, 2021, 76(10)：2636-2639.
|
| 21 |
Vironneau P, Kania R, Morizot G, et al. Local control of rhino-orbito-cerebral mucormycosis dramatically impacts survival[J]. Clin Microbiol Infect, 2014, 20(5)：O336-O339.
|
| 22 |
Gebremariam T, Liu M, Luo G, et al. CotH3 mediates fungal invasion of host cells during mucormycosis[J]. J Clin Invest, 2014, 124(1)：237-250.
|
| 23 |
Warkentien TE, Shaikh F, Weintrob AC, et al. Impact of mucorales and other invasive molds on clinical outcomes of polymicrobial traumatic wound infections[J]. J Clin Microbiol, 2015, 53(7)：2262-2270.
|
| 24 |
Gebremariam T, Alkhazraji S, Soliman SSM, et al. Anti-CotH3 antibodies protect mice from mucormycosis by prevention of invasion and augmenting opsonophagocytosis[J]. Sci Adv, 2019, 5(6)：eaaw1327.
|
| 25 |
Gu Y, Singh S, Alqarihi A, et al. A humanized antibody against mucormycosis targets angioinvasion and augments the host immune response[J]. Sci Transl Med, 2025, 17(789)：eads7369.
|
| 26 |
Moreno A, Mah J, Budvytiene I, et al. Dynamics and prognostic value of plasma cell-free DNA PCR in patients with invasive aspergillosis and mucormycosis[J]. J Clin Microbiol, 2024, 62(5)：e0039424.
|
| 27 |
Kavaliauskas P, Gu Y, Hasin N, et al. Multiple roles for hypoxia inducible factor 1-alpha in airway epithelial cells during mucormycosis[J]. Nat Commun, 2024, 15(1)：5282.
|
| 28 |
Andrianaki AM, Kyrmizi I, Thanopoulou K, et al. Iron restriction inside macrophages regulates pulmonary host defense against Rhizopus species[J]. Nat Commun, 2018, 9(1)：3333.
|
| 29 |
Ibrahim AS, Voelz K. The mucormycete-host interface[J]. Curr Opin Microbiol, 2017, 40：40-45.
|